Biosight is developing innovative therapeutics for hematological malignancies and disorders.
Our lead product, aspacytarabine (BST-236), is an innovative proprietary anti-metabolite designed to enable high-dose therapy with reduced systemic toxicity.
As such, aspacytarabine may serve as an ideal therapy for leukemia, particularly for delivering high doses of cytarabine to medically unfit or older adults who otherwise cannot be treated by effective doses of chemotherapy.
A recently completed multi-center Phase 2b trial (US and Israel) in first-line treatment of AML patients unfit for standard chemotherapy, demonstrates strong single-agent activity, including in patients with poor prognosis such as patietns with prior HMA therapy.
Aspacytarabine is currently being investigated as a single-agent in two Phase 2b trials for firsecond line treatment of AML and myelodysplastic syndrome (MDS):